ARS Pharmaceuticals (SPRY) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $4.02, -1.23% vs the prior close of $4.07.
- Volume 2.33M shares, 1.5x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
SPRY dips 1.2% to $4.02. Closed at $4.02, -1.23% vs the prior close of $4.07. Day range $3.81–$4.08, opened at $4.08.
SPRY daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — SPRY dips 1.2% to $4.02
- Closed at $4.02, -1.23% vs the prior close of $4.07. Day range $3.81–$4.08, opened at $4.08.
- Volume was 2.33M shares, 1.5x its 50-day average of 1.60M.
- Price is -19.4% vs its 50-day average ($4.99) and -48.3% vs its 200-day average ($7.77).
- 52-week range $3.81–$13.15; today's close sits at 2% of that range, 69.4% below the 52-week high.
Oct 15, 2026 — SPRY jumps 3.6% to $4.07
- Closed at $4.07, +3.56% vs the prior close of $3.93. Day range $3.94–$4.09, opened at $3.99.
- Volume was 2.22M shares, 1.4x its 50-day average of 1.60M.
- Price is -18.9% vs its 50-day average ($5.02) and -47.9% vs its 200-day average ($7.81).
- 52-week range $3.88–$13.15; today's close sits at 2% of that range, 69.0% below the 52-week high.
Oct 14, 2026 — SPRY dips 3.0% to $3.93, a 52-week low, 4 down days in a row
- Closed at $3.93, -2.96% vs the prior close of $4.05. Day range $3.88–$4.09, opened at $4.01.
- Volume was 1.73M shares, 1.1x its 50-day average of 1.61M.
- Price is -22.1% vs its 50-day average ($5.05) and -49.9% vs its 200-day average ($7.85).
- 52-week range $3.88–$13.15; today's close sits at 0% of that range, 70.1% below the 52-week high.
- That makes 4 straight losses.
Oct 13, 2026 — SPRY slides 3.1% to $4.05, a 52-week low, 3 down days in a row
- Closed at $4.05, -3.11% vs the prior close of $4.18. Day range $3.99–$4.18, opened at $4.18.
- Volume was 1.55M shares, 1.0x its 50-day average of 1.62M.
- Price is -20.2% vs its 50-day average ($5.07) and -48.6% vs its 200-day average ($7.88).
- 52-week range $3.98–$13.15; today's close sits at 1% of that range, 69.2% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — SPRY dips 1.2% to $4.18
- Closed at $4.18, -1.18% vs the prior close of $4.23. Day range $4.06–$4.27, opened at $4.20.
- Volume was 1.27M shares, 0.8x its 50-day average of 1.64M.
- Price is -18.1% vs its 50-day average ($5.10) and -47.2% vs its 200-day average ($7.92).
- 52-week range $3.98–$13.15; today's close sits at 2% of that range, 68.2% below the 52-week high.
Oct 9, 2026 — SPRY slides 7.2% to $4.23
- Closed at $4.23, -7.24% vs the prior close of $4.56. Day range $4.20–$4.55, opened at $4.53.
- Volume was 1.26M shares, 0.8x its 50-day average of 1.64M.
- Price is -17.4% vs its 50-day average ($5.12) and -46.8% vs its 200-day average ($7.95).
- 52-week range $3.98–$13.15; today's close sits at 3% of that range, 67.8% below the 52-week high.
Oct 8, 2026 — SPRY jumps 4.6% to $4.56, 4 up days in a row
- Closed at $4.56, +4.59% vs the prior close of $4.36. Day range $4.21–$4.64, opened at $4.35.
- Volume was 1.58M shares, 0.9x its 50-day average of 1.74M.
- Price is -11.5% vs its 50-day average ($5.15) and -42.9% vs its 200-day average ($7.99).
- 52-week range $3.98–$13.15; today's close sits at 6% of that range, 65.3% below the 52-week high.
- That makes 4 straight gains.
Oct 7, 2026 — SPRY rises 1.5% to $4.36, 3 up days in a row
- Closed at $4.36, +1.51% vs the prior close of $4.30. Day range $4.20–$4.40, opened at $4.24.
- Volume was 1.30M shares, 0.7x its 50-day average of 1.74M.
- Price is -15.8% vs its 50-day average ($5.18) and -45.6% vs its 200-day average ($8.02).
- 52-week range $3.98–$13.15; today's close sits at 4% of that range, 66.8% below the 52-week high.
- That makes 3 straight gains.
Oct 6, 2026 — SPRY ends flat (+0.1%) to $4.30
- Closed at $4.30, +0.12% vs the prior close of $4.29. Day range $4.08–$4.31, opened at $4.31.
- Volume was 1.22M shares, 0.7x its 50-day average of 1.75M.
- Price is -17.4% vs its 50-day average ($5.20) and -46.6% vs its 200-day average ($8.05).
- 52-week range $3.98–$13.15; today's close sits at 3% of that range, 67.3% below the 52-week high.
Oct 5, 2026 — SPRY jumps 5.4% to $4.29
- Closed at $4.29, +5.41% vs the prior close of $4.07. Day range $4.03–$4.39, opened at $4.13.
- Volume was 1.62M shares, 0.9x its 50-day average of 1.79M.
- Price is -18.0% vs its 50-day average ($5.23) and -46.9% vs its 200-day average ($8.08).
- 52-week range $3.98–$13.15; today's close sits at 3% of that range, 67.4% below the 52-week high.
Oct 2, 2026 — SPRY dips 1.2% to $4.07, a 52-week low, 3 down days in a row
- Closed at $4.07, -1.21% vs the prior close of $4.12. Day range $3.98–$4.27, opened at $4.16.
- Volume was 1.83M shares, 1.0x its 50-day average of 1.81M.
- Price is -22.7% vs its 50-day average ($5.26) and -49.8% vs its 200-day average ($8.11).
- 52-week range $3.98–$13.15; today's close sits at 1% of that range, 69.0% below the 52-week high.
- That makes 3 straight losses.
SPRY latest news & SEC filings
Every SEC filing by or about SPRY in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 30, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 11, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 11, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 4, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 13, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $33.66M (prior year $15.72M) (+114.2% vs Jun 30, 2025)
- Net income: -$62.34M (prior year -$44.88M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.63 (prior year -$0.46) (loss widened vs Jun 30, 2025)
Aug 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 27, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 17, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Jul 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Jun 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade SPRY
- Last results release: Aug 13, 2026 (8-K Item 2.02). Previous ones: May 15, 2026, Mar 9, 2026, Nov 10, 2025. Based on that rhythm, the next report is likely around Nov 12, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.21% (largest 7.2%). That is a volatile stock.
- Liquidity: about 1.47M shares (≈$5.90M) trade per day on average.
- 52-week position: $4.02 vs a range of $3.81–$13.15 (2% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 20 sales; latest: Eric Karas sold 25,000 shares on Jun 12, 2026.
- Latest filings: 10-Q Aug 13, 2026; 8-K Aug 13, 2026; 8-K Jul 17, 2026.
- Share count: 99.45M shares outstanding (Aug 11, 2026), +0.6% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
SPRY market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 4.08 | 4.08 | 3.81 | 4.02 | 2.33M |
| Oct 15, 2026 | 3.99 | 4.09 | 3.94 | 4.07 | 2.22M |
| Oct 14, 2026 | 4.01 | 4.09 | 3.88 | 3.93 | 1.73M |
| Oct 13, 2026 | 4.18 | 4.18 | 3.99 | 4.05 | 1.55M |
| Oct 12, 2026 | 4.20 | 4.27 | 4.06 | 4.18 | 1.27M |
| Oct 9, 2026 | 4.53 | 4.55 | 4.20 | 4.23 | 1.26M |
| Oct 8, 2026 | 4.35 | 4.64 | 4.21 | 4.56 | 1.58M |
| Oct 7, 2026 | 4.24 | 4.40 | 4.20 | 4.36 | 1.30M |
| Oct 6, 2026 | 4.31 | 4.31 | 4.08 | 4.30 | 1.22M |
| Oct 5, 2026 | 4.13 | 4.39 | 4.03 | 4.29 | 1.62M |
| Oct 2, 2026 | 4.16 | 4.27 | 3.98 | 4.07 | 1.83M |
| Oct 1, 2026 | 4.35 | 4.39 | 4.11 | 4.12 | 1.97M |
| Sep 30, 2026 | 4.43 | 4.45 | 4.24 | 4.31 | 1.30M |
| Sep 29, 2026 | 4.11 | 4.43 | 4.01 | 4.40 | 1.27M |
| Sep 28, 2026 | 4.06 | 4.19 | 4.00 | 4.13 | 949.80K |
| Sep 25, 2026 | 4.18 | 4.18 | 4.02 | 4.08 | 1.03M |
| Sep 24, 2026 | 4.21 | 4.24 | 4.07 | 4.15 | 1.05M |
| Sep 23, 2026 | 4.49 | 4.49 | 4.11 | 4.18 | 1.37M |
| Sep 22, 2026 | 4.40 | 4.57 | 4.36 | 4.48 | 1.27M |
| Sep 21, 2026 | 4.16 | 4.39 | 4.07 | 4.35 | 1.20M |
About ARS Pharmaceuticals
ARS Pharmaceuticals (SPRY) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1671858.
SPRY board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Rajeev Dadoo | Director | Jun 26, 2026 |
| Saqib Islam | Director | Jun 26, 2026 |
| Michael Kelly | Director | Jun 26, 2026 |
| Peter Kolchinsky | Director | Jun 26, 2026 |
| Richard E Lowenthal | PRESIDENT AND CEO | Jan 5, 2026 |
| Capital Management, L.P. Ra | Director | Jun 26, 2026 |
| Capital Healthcare Fund Lp Ra | Director | Jun 26, 2026 |
| Capital Nexus Fund Ii, L.P. Ra | Director | Jun 26, 2026 |
| Brent L Saunders | Director | Jun 26, 2026 |
| Phillip M Schneider | Director | Jun 26, 2026 |
| Pratik Shah | Director | Jun 26, 2026 |
| Rajeev M. Shah | Director | Jun 26, 2026 |
| Laura Shawver | Director | Jun 26, 2026 |
| Peter A. Thompson | Director | Jun 26, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Donn Casale | President | Jul 2, 2026 |
| Justin Chakma | Chief Business Officer | Jan 5, 2026 |
| Brian Dorsey | Chief Operating Officer | Jan 5, 2026 |
| Alexander A Fitzpatrick | Chief Legal Officer | Jun 12, 2026 |
| Eric Karas | Chief Commercial Officer | Jun 12, 2026 |
| Richard E Lowenthal | PRESIDENT AND CEO | Jan 5, 2026 |
| Kathleen D. Scott | Chief Financial Officer | Jan 5, 2026 |
| Margaret Ekins Smith | Chief Commercial Officer | Sep 2, 2026 |
| Sarina Tanimoto | CHIEF MEDICAL OFFICER | Jan 5, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 12, 2026 | Eric Karas | Sale | 25,000 | $10.00 |
| Jun 12, 2026 | Eric Karas | Sale | 25,000 | $10.00 |
| Jun 12, 2026 | Eric Karas | Sale | 25,000 | $10.00 |
| Jun 12, 2026 | Eric Karas | Sale | 25,000 | $10.00 |
| Jun 12, 2026 | Alexander A Fitzpatrick | Sale | 3,355 | $10.00 |
| Jun 12, 2026 | Alexander A Fitzpatrick | Sale | 3,355 | $10.00 |
| Jun 12, 2026 | Alexander A Fitzpatrick | Sale | 3,355 | $10.00 |
| Jun 12, 2026 | Alexander A Fitzpatrick | Sale | 3,355 | $10.00 |
| Nov 13, 2025 | Brian Dorsey | Sale | 21,828 | $8.71 |
| Nov 13, 2025 | Brian Dorsey | Sale | 21,828 | $8.71 |
| Nov 13, 2025 | Brian Dorsey | Sale | 21,828 | $8.71 |
| Nov 13, 2025 | Brian Dorsey | Sale | 21,828 | $8.71 |
| Nov 12, 2025 | Justin Chakma | Sale | 136,380 | $8.86 |
| Nov 12, 2025 | Justin Chakma | Sale | 30,000 | $8.91 |
| Nov 12, 2025 | Justin Chakma | Sale | 136,380 | $8.86 |
SPRY financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $84.28M | $-171.30M | -1.74 | $-170.87M |
| Dec 31, 2024 | $89.15M | $8.00M | 0.08 | $13.55M |
| Dec 31, 2023 | $30.00K | $-54.37M | -0.57 | $-59.27M |
| Dec 31, 2022 | $1.32M | $-34.68M | -0.87 | $-40.08M |
| Dec 31, 2021 | $5.51M | $-20.24M | -0.70 | $-17.56M |
Latest balance sheet: total assets $249.50M, total liabilities $236.98M, cash $8.16M (as of Jun 30, 2026).
SPRY earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 13, 2026 | 8-K Item 2.02 (results) | $6.10 |
| May 15, 2026 | 8-K Item 2.02 (results) | $7.43 |
| Mar 9, 2026 | 8-K Item 2.02 (results) | $9.05 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $8.88 |
| Aug 13, 2025 | 8-K Item 2.02 (results) | $15.82 |
| May 14, 2025 | 8-K Item 2.02 (results) | $12.10 |
| Mar 20, 2025 | 8-K Item 2.02 (results) | $14.31 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $11.26 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $14.08 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Mar 21, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on SPRY
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.